SEC Company Response from Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805) (NAUT) — May 12, 2021
Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805)
Date: May 12, 2021 · CIK: 0001808805 · Accession: 0001628280-21-010070
AI Filing Summary & Sentiment
File numbers found in text: 333-254796
Show Raw Text
CORRESP 1 filename1.htm Document ARYA Sciences Acquisition Corp III 51 Astor Place, 10th Floor New York, NY 10003 May 12, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Abby Adams and Joe McCann Re: ARYA Sciences Acquisition Corp III Amendment No. 3 to Registration Statement on Form S-4 File No. 333-254796 Dear Ms. Adams and Mr. McCann: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ARYA Sciences Acquisition Corp III (the “Company”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 4 p.m., Eastern Time, on May 13, 2021, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Kirkland & Ellis LLP, request by telephone that such Registration Statement be declared effective. Please contact Peter S. Seligson, of Kirkland & Ellis LLP, special counsel to the Company, at (212) 446-4756, as soon as the registration statement has been declared effective, or if you have any other questions or concerns regarding this matter. Sincerely, /s/ Adam Stone Adam Stone Chief Executive Officer